A Study of LY3016859 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY3016859 intravenous
Drug: Placebo intravenous
Drug: Placebo subcutaneous
Drug: LY3016859 subcutaneous

Registration Number: NCT01545583

Lead Sponsor: Eli Lilly and Company

Brief Summary: The purpose of this study is to investigate the safety and tolerability of LY3016859 administered as single doses, and to determine how long LY3016859 remains in the body

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 56

Inclusion Criteria

Healthy men and women of non-childbearing potential as determined by medical history and physical examination (PE), and:
- Men agree to use 2 medically accepted methods of contraception with all sexual partners during the study and for 90 days after the final dose
- Women are not of child-bearing potential due to surgical sterilization (at least 6 weeks after surgical bilateral oophorectomy with or without hysterectomy or at least 6 weeks after tubal ligation) confirmed by medical history, or post-menopause. Post-menopausal status will be defined as a woman 45 years of age or older with either 12 months of spontaneous amenorrhea, or 6-12 months of spontaneous amenorrhea combined with follicle stimulating hormone (FSH) greater than (>) 40 international units per liter (IU/L)
Are reliable and are willing to make themselves available for the duration of the study, and are willing to follow site specific study procedures
Must weigh greater than or equal to (≥) 50 kilograms (kg) at time of screening and dosing
Have clinical laboratory test results within normal reference range for the investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
Have venous access sufficient to allow blood sampling as per the protocol
Must be a non-smoker

Exclusion Criteria

Are currently enrolled in, or have discontinued within the last 60 days from a clinical trial involving an investigational drug that has not received regulatory approval for any indication, or have received treatment with biologic agents (such as monoclonal antibodies) within 3 months or 5 half-lives of the administered drug (whichever is longer) prior to dosing
Have previously completed or withdrawn from this study or any other study investigating LY3016859, and have previously received the investigational product
Have a history or presence of medical illness including but not limited to any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, or any clinically significant laboratory abnormality, that in the judgment of the investigator indicates a medical problem that would preclude study participation
Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study or have:
- Confirmed corrected QT interval using Fridericia's formula (QTcF) > 450 milliseconds (msec) for men and > 470 msec for women
- Bundle branch blocks or other conduction abnormalities other than mild first-degree atrio-ventricular block
- Irregular rhythms other than sinus arrhythmia or occasional, rare supraventricular ectopic beats
- History of unexplained syncope
- Family history of unexplained sudden death or sudden death due to long QT syndrome
- T-wave configurations are not of sufficient quality for assessing QT interval, as determined by the investigator
Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies, hepatitis C and/or positive hepatitis C antibody, or Hepatitis B and/or positive Hepatitis B surface antigen
Show use of any medication with potential to mask allergic response for example (e.g.) antihistamines, systemic glucocorticoids or antipyretic agents) within 3 days of dosing (Note: Acetaminophen or nonsteroidal analgesics for headache may be allowed as needed in the Investigator's judgment. The following medications are also specifically allowed in this study: vitamins at normal replacement doses, hormone replacement therapies e.g. estrogen, thyroid hormone), topical medications with limited systemic effects (e.g. eye drops, skin creams, vaginal antifungals, hemorrhoid preparations, etcetera (etc.), stable preventive therapies for hyperlipidemia and gastric acidity disorders)
Have donated blood of more than 500 milliliters (mL) within the last month.
Have an average weekly alcohol intake that exceeds 21 units per week or are unwilling to stop alcohol within 48 hours of entry into study and for the duration of the study [1 unit = 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits]
Have an abnormal blood pressure (sitting) defined as diastolic blood pressure (DBP) > 95 or less than (<) 50 millimeters of mercury (mmHg) and/or systolic blood pressure (SBP) > 150 or < 90 mmHg confirmed by at least 1 repeat measurement
Have evidence of regular use of known drugs of abuse or show positive findings for such use on urinary drug screening
Will donate blood or participate in another clinical trial within 3 months or 5 half-lives of study drug (whichever is longer) of receiving the last study drug administration

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1 mg LY3016859 intravenous	LY3016859 intravenous	1 mg LY3016859 administered once intravenously
10 mg LY3016859 intravenous	LY3016859 intravenous	10 mg LY3016859 administered once intravenously
Placebo intravenous	Placebo intravenous	Placebo administered once intravenously
50 mg LY3016859 intravenous	LY3016859 intravenous	50 mg LY3016859 administered once intravenously
250 mg LY3016859 intravenous	LY3016859 intravenous	250 mg LY3016859 administered once intravenously
Placebo subcutaneous	Placebo subcutaneous	Placebo administered once subcutaneously
0.1 milligram (mg) LY3016859 intravenous	LY3016859 intravenous	0.1 mg LY3016859 administered once intravenously
750 mg LY3016859 intravenous	LY3016859 intravenous	750 mg LY3016859 administered once intravenously
50 mg LY3016859 subcutaneous	LY3016859 subcutaneous	50 mg LY3016859 administered once subcutaneously

Primary Outcome Measures

Name	Time	Method
Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs) or Any Serious AEs (SAE)	From baseline up to 8 weeks post dose	Drug-related TEAEs are any untoward medical occurrence that either occurs or worsens at any time after treatment baseline, and in the opinion of the investigators is possibly related to study drug. A summary of SAEs and other nonserious AEs, regardless of whether or not they were possibly related to study drug, is located in the Reported Adverse Event section.

Secondary Outcome Measures

Name	Time	Method
Pharmacodynamics: Area Under the Concentration-Time Curve (AUC) of Serum Epiregulin	Predose up to 8 weeks post dose
Pharmacodynamics: Area Under the Concentration-Time Curve (AUC) of Serum Transforming Growth Factor Alpha (TGFα)	Predose up to 8 weeks post dose
Pharmacokinetics: Maximum Serum Concentration (Cmax) of LY3016859	Predose up to 8 weeks post dose
Pharmacokinetics: Area Under the Serum Concentration-Time Curve (AUC) of LY3016859 From Time Zero to Infinity (AUC0-inf)	Predose up to 8 weeks post dose

Trial Locations

Locations (1): For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇬🇧
London, United Kingdom